US4359458A
Expired / Lapsed
US
⏱️ 0.0 years remaining
O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
Assignee: Wyeth Holdings LLC
•
Filing: 1981-09-28
•
Granted: 1982-11-16
•
Expires: 2001-09-28
Abstract
Abstract O- beta -D (and O- alpha -D) multi-galactopyranosyl (or xylopyranosyl or glucopyranosyl) 1 alpha ,1 alpha ' galactopyranosyl (or xylopyranosyl or glucopyranosyl) sulfate salts, useful as complement inhibitors, the intermediates thereof and the process for preparation of such compounds.
Inventors
- 👤 Vijay G. Nair
- 👤 Joseph P. Joseph
- 👤 Arthur J. Lewis
- 👤 Seymour Bernstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 13:44
CPC Classifications
C; C07; C07H; C07H3/00; C07H3/06
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
109 words
A compound selected from those of the formula: ##STR27## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, are selected from the group consisting of ##STR28## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR29##
Claim 2
Dependent Claim
109 words
A compound selected from those of the formula: ##STR27## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, are selected from the group consisting of ##STR28## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR29##
Claim 3
Dependent Claim
18 words
The compound according to claim 1, [gal 1β,6 glc 1α,1α' glc 1β,6 gal, tetradecakis (H-sulfate), tetradecasalt with trimethylamine].
Claim 4
Dependent Claim
17 words
The compound according to claim 1, [gal 1β,6 glc 1α,1α' glc 1β,6 gal, tetradecakis (H-sulfate), tetradecasodium salt].
Claim 5
Dependent Claim
18 words
The compound according to claim 1, [xyl 1β,6 glc 1α,1α' glc 1β,6 xyl, dodecakis (H-sulfate), dodecasalt with trimethylamine].
Claim 6
Dependent Claim
18 words
The compound according to claim 1, [xyl 1β,6 glc 1α, 1α' glc 1β,6 xyl, dodecakis (H-sulfate), dodecasodium salt].
Claim 7
Dependent Claim
22 words
The compound according to claim 1, [glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc, eicosakis (H-sulfate), eicosasalt with trimethylamine].
Claim 8
Dependent Claim
22 words
The compound according to claim 1, [glc 1α,4 glc 1β,6 glc 1α, 1α' glc 1β,6 glc 1α,4 glc, eicosakis (H-sulfate), eicosasodium salt].
Claim 9
Dependent Claim
26 words
The compound according to claim 1, [glc 1α,4 glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc 1α,4 glc, hexacosakis (H-sulfate), hexacosasalt with trimethylamine].
Claim 10
Dependent Claim
25 words
The compound according to claim 1, [glc 1α,4 glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc 1α,4 glc, hexacosakis (H-sulfate), hexacosasodium salt].
Claim 11
Dependent Claim
28 words
The compound according to claim 1, [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc 1β,6 glc (glc 1α,4) 5 1α,4 glc, pentacontakis (H-sulfate), pentacontasalt with trimethylamine].
Claim 12
Dependent Claim
27 words
The compound according to claim 1, [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc 1β,6 glc (glc 1α,4) 5 1α,4 glc, pentacontakis (H-sulfate) pentacontasodium salt].
Claim 13
Dependent Claim
21 words
The compound according to claim 1, [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc, nonacosakis (H-sulfate), nonacosasalt with trimethylamine].
Claim 14
Dependent Claim
20 words
The compound according to claim 1, [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc, nonacosakis (H-sulfate), nonacosasodium salt].
Claim 15
Dependent Claim
45 words
A compound selected from those of the formula: ##STR30## wherein M and P, when they are the same, are selected from the group consisting of ##STR31## and M and P, when they are different, are each selected from the group consisting of OH and ##STR32##
Claim 16
Dependent Claim
45 words
A compound selected from those of the formula: ##STR30## wherein M and P, when they are the same, are selected from the group consisting of ##STR31## and M and P, when they are different, are each selected from the group consisting of OH and ##STR32##
Claim 17
Independent Claim
136 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR33## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, are selected from the group consisting of ##STR34## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR35##
Claim 18
Independent Claim
136 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR33## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, are selected from the group consisting of ##STR34## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR35##
Claim 19
Dependent Claim
13 words
The method according to claim 15, wherein the body fluid is blood serum.
Claim 20
Independent Claim
135 words
A method of inhibiting the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR36## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, as selected from the group consisting of ##STR37## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR38##
Claim 21
Independent Claim
135 words
A method of inhibiting the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR36## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); R and R', when they are the same, as selected from the group consisting of ##STR37## wherein A is as hereinabove defined; and R and R', when they are different, are each selected from the group consisting of --OSO 3 A and ##STR38##
Claim 22
Dependent Claim
24 words
The method according to claim 15 or 17, wherein the compound is [gal 1β,6 glc 1α,1α' glc 1β,6 gal, tetradecakis (H-sulfate), tetradecasalt with trimethylamine].
Claim 23
Dependent Claim
23 words
The method according to claim 15 or 17, wherein the compound is [gal 1β,6 glc 1α,1α' glc 1β,6 gal, tetradecakis (H-sulfate), tetradecasodium salt].
Claim 24
Dependent Claim
24 words
The method according to claim 15 or 17, wherein the compound is [xyl 1β,6 glc 1α,1α' glc 1β,6 xyl, dodecakis (H-sulfate), dodecasalt with trimethylamine].
Claim 25
Dependent Claim
23 words
The method according to claim 15 or 17, wherein the compound is [xyl 1β,6 glc 1α,1α' glc 1β,6 xyl, dodecakis (H-sulfate), dodecasodium salt].
Claim 26
Dependent Claim
28 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 gl 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc, eicosakis (H-sulfate), eicosasalt with trimethylamine].
Claim 27
Dependent Claim
27 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc, eicosakis (H-sulfate), eicosasodium salt].
Claim 28
Dependent Claim
32 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc 1α,4 glc, hexacosakis (H-sulfate), hexacosasalt with trimethylamine].
Claim 29
Dependent Claim
31 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 glc 1α,4 glc 1β,6 glc 1α,1α' glc 1β,6 glc 1α,4 glc 1α,4 glc, hexacosakis (H-sulfate), hexacosasodium salt].
Claim 30
Dependent Claim
34 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc 1β,6 glc (glc 1α,4) 5 1α,4 glc, pentacontakis (H-sulfate), pentacontasalt with trimethylamine].
Claim 31
Dependent Claim
33 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc 1β,6 glc (glc 1α,4) 5 1α,4 glc, pentacontakis (H-sulfate), pentacontasodium salt].
Claim 32
Dependent Claim
27 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 (glc 1α,4) 5 glc 1β,6 glc 1α,1α' glc, nonacosakis (H-sulfate), nonacosasalt with trimethylamine].
Claim 33
Dependent Claim
26 words
The method according to claim 15 or 17, wherein the compound is [glc 1α,4 (glc 1α,4) 5 glc 1α,6 glc 1α,1α' glc, nonacosakis (H-sulfate), nonacosasodium salt].
Claim 34
Dependent Claim
12 words
The method according to claim 17, wherein the compound is administered internally.
Claim 35
Dependent Claim
12 words
The method according to claim 17, wherein the compound is administered topically.
Claim 36
Dependent Claim
16 words
The method according to claim 17, wherein the compound is administered periodontally in the oral cavity.
Claim 37
Dependent Claim
12 words
The method according to claim 17, wherein the compound is administered intra-articularly.
Claim 38
Dependent Claim
12 words
The method according to claim 17, wherein the compound is administered parenterally.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-11-15 | 1986-05-17 | 1986-11-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-11-15 | 1990-05-17 | 1990-11-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-11-15 | 1994-05-17 | 1994-11-16 | $7700.00 | Window Closed / Lapsed |